These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 4538545)

  • 1. The risk of transmission from lepromatous leprosy cases under therapy.
    Worth RM
    Bull World Health Organ; 1972; 46(6):853-4. PubMed ID: 4538545
    [No Abstract]   [Full Text] [Related]  

  • 2. Further notes on the incidence of leprosy in Hong Kong children living with a lepromatous parent.
    Worth RM; Wong KO
    Int J Lepr Other Mycobact Dis; 1971; 39(3):745-9. PubMed ID: 5169925
    [No Abstract]   [Full Text] [Related]  

  • 3. Is it safe to treat the lepromatous patient at home? A study of home exposure to leprosy in Hong Kong.
    Worth RM
    Int J Lepr Other Mycobact Dis; 1968; 36(3):296-302. PubMed ID: 5749656
    [No Abstract]   [Full Text] [Related]  

  • 4. [Quadriplegia, in lepromatous leprosy previously cleared-up, diffuse polyneuritis which appeared in spite of 6 years of follow-up consolidating treatment with Sultirene alone].
    Merklen FP; Cottenot F; Pennec J; Vernant JC; Buzacoux J
    Bull Soc Fr Dermatol Syphiligr; 1971; 78(4):461-2. PubMed ID: 5150887
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of leprosy by sulfones and delayed-action sulfonamides: comparison of therapeutic results in 100 cases].
    Privat Y; Faye I; Bellossi A
    Mars Med; 1968; 105(3):276-80. PubMed ID: 5754252
    [No Abstract]   [Full Text] [Related]  

  • 6. Maintenance of leprosy endemicity and bacterial positivity of lepromatous patients under treatment with sulfones.
    Bechelli LM; Dominguez VM
    Int J Lepr Other Mycobact Dis; 1971; 39(2):461. PubMed ID: 5169809
    [No Abstract]   [Full Text] [Related]  

  • 7. The treatment of leprosy with the sulfones. I. Faget's original 22 patients. A thirty-year follow-up on sulfone therapy for leprosy.
    Jacobson RR; Trautman JR
    Int J Lepr Other Mycobact Dis; 1971; 39(3):726-37. PubMed ID: 4948221
    [No Abstract]   [Full Text] [Related]  

  • 8. Follow up study of thirty-six borderline cases of leprosy.
    Kundu S; Ghosh S
    Bull Calcutta Sch Trop Med; 1967 Jul; 15(3):103-4. PubMed ID: 5616299
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comments on 9 cases of lepromatous leprosy].
    Puissant A; Pringuet R; Pradinaud R
    Bull Soc Fr Dermatol Syphiligr; 1968; 75(1):20-6. PubMed ID: 5674296
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of leprosy by sulfones and delayed action sulfonamides. Comparison of therapeutic results in 100 cases].
    Faye I; Privat Y; Bellossi A
    Bull Soc Med Afr Noire Lang Fr; 1968; 13(1):119-24. PubMed ID: 5713742
    [No Abstract]   [Full Text] [Related]  

  • 11. Australia antigen and lepromatous leprosy studies in South India and elsewhere.
    Blumberg BS; Melartin L
    Int J Lepr Other Mycobact Dis; 1970; 38(1):60-7. PubMed ID: 4991886
    [No Abstract]   [Full Text] [Related]  

  • 12. Further observations on streptomycin combined with sulfones in relapsed lepromatous leprosy.
    Hastings RC; Trautman JR; Mansfield RE
    Int J Lepr Other Mycobact Dis; 1969; 37(2):130-4. PubMed ID: 5389014
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of single dose (1500 mg) rifampicin on infectivity of patients with lepromatous leprosy.
    Girdhar BK; Sreevatsa ; Desikan KV
    Lepr India; 1980 Jul; 52(3):359-65. PubMed ID: 7206633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leprosy.
    Hendrick SS; Wilkin JK
    Am Fam Physician; 1982 Nov; 26(5):161-6. PubMed ID: 7148625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The condition of the peripheral nerve in leprosy under various forms of treatment. Conduction velocity studies in long-term follow-up.
    Magora A; Sheskin J; Sagher F; Gonen B
    Int J Lepr Other Mycobact Dis; 1970; 38(2):149-63. PubMed ID: 5529246
    [No Abstract]   [Full Text] [Related]  

  • 16. [Late evolutive recurrences of formerly treated leprosy].
    Merklen FP; Cottenot F; Pennec J; Blanchet P
    Bull Soc Fr Dermatol Syphiligr; 1971; 78(4):459-61. PubMed ID: 5170176
    [No Abstract]   [Full Text] [Related]  

  • 17. Bacterial negativity and reactivation (relapse) of lepromatous outpatients under sulfone treatment.
    Quagliato R; Bechelli LM; Marques RM
    Int J Lepr Other Mycobact Dis; 1970; 38(3):250-63. PubMed ID: 4993550
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperreflexia and spastic paralysis among New Caledonian leprosy patients.
    Brody JA; Yase Y; Chemier G; Philippe Y
    Am J Trop Med Hyg; 1969 Jan; 18(1):132-7. PubMed ID: 5764193
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary dapsone resistant leprosy in Nepal.
    Samuel NM; Samuel S; Loudon J; Adiga RB
    Indian J Lepr; 1984; 56(4):819-22. PubMed ID: 6398343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination of red sarsaparilla & 4,4'-diaminodiphenylsulfone in therapy of lepromatous leprosy; study of 73 cases].
    ROLLIER R
    Maroc Med; 1957 Nov; 36(390):1106-28. PubMed ID: 13515628
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.